In:
The Prostate, Wiley
Abstract:
The treatment and surveillance of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved since the introduction of several treatment intensification options associated with hormonal blockade and classifications based on the timing of metastatic disease presentation and disease volume. Using a hospital‐based registry, we aimed to assess whether these new classifications are applicable to our population, as few studies have demonstrated their prognostic value for overall survival (OS) and time to development of castration‐resistant prostate cancer (CRPC), and to establish prognostic factors in our population. Methods A retrospective cohort of mHSPC patients who were attended at an oncology referral hospital in Bogota between 2017 and 2021 were included in this study. The primary and secondary endpoints were OS and time to CRPC. The distribution of outcome measures was estimated using the Kaplan–Meier method. Proportional hazard models were constructed using the Cox regression approach and stratified according to risk factors. Results The study cohort included 373 patients. The median castration resistance‐free survival was 48 months (CI: 32–73 months), and OS was 43 months (CI: 37–48 months). In multivariate analysis, nodal staging, ECOG status, and surgical castration were independent prognostic factors. Conclusion In our hospital‐based registry, the independent impact of the time of presentation on castration‐resistant‐free survival or OS could not be demonstrated, nor could the grouping of prognostic categories based on metastatic presentation temporality and volume. Other independent prognostic factors have been proposed.
Type of Medium:
Online Resource
ISSN:
0270-4137
,
1097-0045
Language:
English
Publisher:
Wiley
Publication Date:
2024
detail.hit.zdb_id:
1494709-2
